Novo Nordisk
-
Cardiologists Confront Fundamental Uncertainty After High-Profile Trial Failures
Stunning clinical trial failures of two high-profile heart drugs presented on Nov 7, 2026, force a critical re-evaluation of cardiovascular disease theories.
-
Todd Engel Files Lawsuit After Ozempic Use Precedes Vision Loss
Maryland resident Todd Engel has filed a lawsuit against Novo Nordisk after suffering permanent vision loss in both eyes following Ozempic use.
-
Regulatory Safety Scrutiny and the Multi-Billion Dollar Oral Obesity Duel: The Evolving Clinical Stakes of GLP-1 Therapies
As regulators investigate pancreatitis cases and rare gastrointestinal conditions, Eli Lilly and Novo Nordisk engage in a high-stakes oral obesity market duel.
-
Novo Nordisk Targets Australian Market for Wegovy Pill Expansion
Following its UK debut, Novo Nordisk is eyeing an Australian launch for its oral weight-loss drug Wegovy, pending local regulatory approval.
-
Novo Nordisk Hikes Guidance as Wegovy Pill Sales Outpace Rivals
Novo Nordisk has raised its 2026 outlook following a strong debut for the Wegovy oral tablet in the U.S. market, signaling a pivotal shift in the competitive landscape for obesity treatments.
-
Novo Nordisk Shares Rebound After Recent Valuation Slide
Novo Nordisk shares climbed 3.32% on Tuesday, marking a notable recovery following a period of sustained volatility and significant short-term price pressure.
-
Novo Nordisk Gains Momentum with GLP-1 Drug Expansion
The success of GLP-1 therapies like Ozempic and Wegovy has propelled Novo Nordisk’s stock, reflecting surging global demand for obesity solutions.
-
Beyond Obesity: The Emerging Risks of GLP-1 Medications
As GLP-1 drugs gain popularity for weight loss, new studies highlight potential long-term risks for bone health and metabolism, sparking a debate on their role in modern medicine.
-
Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.
-
Eli Lilly Widens Obesity Drug Lead with Zepbound Wins
Eli Lilly solidified its dominance in the obesity drug market on Monday. New trial data showed Zepbound’s superior efficacy, and a multi-dose KwikPen launched.
-
Novo Nordisk Stock Falls on Disappointing CagriSema Trial Results
Novo Nordisk A/S (NVO) shares dropped pre-market after its experimental obesity drug, CagriSema, failed to meet its primary endpoint in a Phase 3 trial, impacting its competitive standing.
-
Wegovy Pill Copy: Hims & Hers Shakes Weight-Loss Drug Market
Telehealth company Hims & Hers announced it will offer a $49 copy of Novo Nordisk’s popular Wegovy pill, causing significant shifts in the stock market for major pharmaceutical firms.
-
Novo Nordisk CEO Unveils Aggressive Strategy to Reclaim GLP-1 Market Lead, Targets 2 Billion People
Novo Nordisk’s new CEO Maziar Mike Doustdar outlines a bold three-pronged strategy for 2026, aiming to reclaim market dominance in the GLP-1 obesity drug sector from rival Eli Lilly. The plan focuses on commercial execution, pipeline progression, and a return…
-
Wegovy Pill Launches: Oral GLP-1 Reshapes Weight Loss Management
Novo Nordisk’s Wegovy pill, the first oral GLP-1 for weight loss, is now broadly available, offering a new, convenient option for millions battling obesity. Learn about its efficacy, cost, and availability.
-
Novo Nordisk Stock Plunges After Alzheimer’s Trial Failure Spurs Turmoil and Fierce Market Competition
Novo Nordisk’s shares nosedived after its Alzheimer’s drug trial failed, intensifying investor concerns amid fierce competition and strategic shifts. The company faces mounting pressure from rivals, regulatory changes, and leadership upheaval, leaving its future direction under scrutiny.